Eli Lilly agrees to buy Calytrix Bio for up to $1.5 billion in cash
Eli Lilly has agreed to acquire privately held Calytrix Bio for up to $1.5 billion in cash, with an upfront payment plus milestone-based payments that Calytrix did not size. The deal adds an early-stage blood disorder treatment to Lilly's hematology business, and it is one more step in the drugmaker's push beyond its diabetes and weight-loss medicines.
Eli Lilly has agreed to buy Calytrix Bio, a privately held biotech company, in a cash deal worth up to $1.5 billion. Reuters reported the agreement on Monday, citing the biotech's own announcement that day.
How the payments are structured
The price includes an upfront payment and additional payments tied to clinical trial and regulatory milestones, according to Reuters. Calytrix did not disclose how large the upfront payment is. It also did not give an expected closing date for the transaction.
Because the milestone payments depend on future events, the $1.5 billion figure is a maximum rather than a fixed price. The company did not say when those milestones might be reached.
What Calytrix is developing
Calytrix's lead candidate is an early-stage antibody treatment aimed at essential thrombocythemia and myelofibrosis. Both are rare blood disorders in which the bone marrow produces too many abnormal blood cells, Reuters said.
Reuters reported that the acquisition is expected to deepen Lilly's presence in hematology. Lilly already sells Jaypirca, an FDA-approved medicine for blood cancer, so the candidate would sit alongside an existing product in that area.
Lilly's wider acquisition effort
Reuters described the purchase as the latest in a series of deals by the Indianapolis-based drugmaker. Lilly is working to reduce its reliance on its diabetes and weight-loss franchise, which remains its main growth engine.
For US investors, the deal is a reminder of how large drugmakers are expanding their pipelines through purchases of young private companies rather than only through internal research. The reporting did not say how the transaction would affect Lilly's financial results or its earnings outlook.
What investors should note
- Eli Lilly is the only publicly traded company named in the agreement, and it trades on the New York Stock Exchange under the ticker LLY.
- Calytrix is privately held, so ordinary investors cannot buy its shares.
- The $1.5 billion figure combines an undisclosed upfront amount with later milestone payments.
- The candidate is still early-stage, and the company did not describe a timeline for clinical or regulatory events.
Lilly's statement on the deal, as summarized by Reuters, is the main source for the terms. Investors who want the full details can check Lilly's and Calytrix's future filings and announcements for updates on the price split and closing.
Sources
- Calytrix Bio enters an agreement to be acquired by Lilly to advance outcomes for patients living with essential thrombocythemia and myelofibrosis prnewswire.com
- Lilly to buy Calytrix Bio for up to $1.5 billion sg.finance.yahoo.com
Written with AI assistance on Nov 16, 12:02 PM ET from the reports listed under Sources, and reviewed by our editor after publication. Before it was published, every figure was checked against those reports, and passages with figures that could not be found there were left out. It can still contain mistakes: read the sources before acting on anything. How we review. Not investment advice.